Dr. Mazyar Shadman and colleagues presented this research at the American Society for Hematology annual meeting, which was held in December 2021 (ASH 2021).
Playing CLL / SLL Chess: Planning Your Therapy Moves Wednesday, October 26, 2022 12 PM PT / 1 PM MT / 2 PM CT / 3 PM ET (Duration 90 minutes) Register Now!
Cellular therapies are a special type of immunotherapy that use cells, a “living drug”, to treat CLL / SLL. CAR-T is a revolutionary therapy in CLL and other blood cancers, which is currently available through clinical trials. Learn more about this “living drug” and other cellular therapy options for CLL patients with Dr. Mazyar Shadman.
Chemotherapy Chemotherapy damages the cells’ DNA and non-specifically kills anything that grows quickly, such as cancer cells, but also skin, hair, gut, and normal blood cells. In CLL / SLL, common
Immunotherapy Immunotherapy works by harnessing the body’s own immune system and offers options for powerful, yet well-tolerated, therapies. Examples include monoclonal antibodies (rituximab, obinutuzumab, and others) that recognize the cancer, drugs
The short answer is that it is certainly beginning to look that way for a lucky few. This month celebrated the 10th CAR-T anniversary of Doug Olson, who remains cancer-free with persistent CAR-T cells that still play WHACK-A-MOLE should any cancerous CLL cells dare to reappear.
At the annual meeting of the American Society of Hematology (ASH) 2020, our own Dr. Brian Koffman interviewed Dr. Neil Kay, a Professor of Medicine and a hematologist at Mayo Clinic. They discussed a new way to potentially enhance the activity of CAR-T cells for treating CLL.
By Paul Bildstein – Patient I was diagnosed in 2009 at age 60 with CLL (Trisomy 12, unmutated) after a routine blood test. Initially on watch and wait, I was treated
CAR-T and Other Cellular Therapies Some of the most exciting advances in blood cancer in general, and in CLL / SLL in particular, are in harnessing and re-engineering the body’s own
© 2025 CLL Society. All Rights Reserved.
Legal | Privacy Policy | Corporate Giving Policy
Terms & Conditions | Report a Bug | Site Design
CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on patient education, support, and research. Dedicated to addressing the unmet needs of the chronic lymphocytic leukemia (CLL) and related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials, support and build patient networks, engage in research, and educate providers and patients.
CLL Society is a registered 501(c)(3) tax-exempt nonprofit organization. All donations are tax-deductible to the greatest extent as allowed under federal law. CLL Society’s tax ID number is 46-4131354.
1454 Melrose Avenue, Ste. 1-247
Chula Vista, CA 91911
